Adverum Biotechnologies is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Co. develops gene therapy product candidates designed to provide efficacy by inducing sustained expression of a therapeutic protein. Co.'s main capabilities include vector discovery, preclinical and clinical development, and in-house manufacturing knowledge, specifically in scalable process development, assay development, and current Good Manufacturing Practices quality control. Co.'s lead product candidate ADVM-022 is a single intravitreal injection gene therapy targeting the treatment of wet age-related macular degeneration and diabetic retinopathy. We show 29 historical shares outstanding datapoints in our coverage of ADVM's shares outstanding history.
Understanding the changing numbers of ADVM shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ADVM versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ADVM by allowing them to research ADVM shares outstanding history
as well as any other stock in our coverage universe. |
Video: Shares Outstanding Importance
